SCHEDULE: Aurum Ventures & Morris Kahn Boost PolyPid Stake to 28.1%

Aurum Ventures M.K.I. Ltd. and Morris Kahn have reported a combined beneficial ownership of 28.1% in PolyPid Ltd., including shares from exercisable warrants.

Summary

• Aurum Ventures M.K.I. Ltd. and Morris Kahn jointly reported beneficial ownership of 5,001,561 Ordinary Shares in PolyPid Ltd.
• This represents 28.1% of PolyPid's outstanding Ordinary Shares.
• The ownership calculation includes 1,918,879 ordinary shares issuable upon the exercise of currently exercisable warrants held by Aurum.
• The percentage is based on 15,897,201 Ordinary Shares outstanding as of July 27, 2025, plus the warrant shares.
• A "blocker" clause in the warrants limits exercise to prevent beneficial ownership above 9.9% at any given time, meaning the actual beneficially owned percentage at any one time is less than reported.
• Morris Kahn is the ultimate sole beneficial shareholder of Aurum and is deemed to share beneficial ownership, though he disclaims day-to-day control.

Sentiment

Score: 7

Explanation: The filing indicates a strong, stable, and significant ownership stake by a major investor, which generally signals confidence. However, the warrant blocker clause introduces a slight complexity regarding the immediate full realization of this stake.

Positives

• Significant long-term investor commitment demonstrated by a substantial 28.1% stake held by Aurum Ventures and Morris Kahn.
• The presence of a large, stable shareholder group can provide corporate stability and potentially align interests with long-term company growth.

Negatives

• The "blocker" clause in the warrants, limiting beneficial ownership to 9.9% at any given time, restricts the immediate full exercise of all warrants, potentially impacting the reporting persons' ability to fully realize their stake or influence.

Risks

• The "blocker" clause in the warrants means the reported 28.1% beneficial ownership is theoretical for immediate full exercise, as actual ownership at any given time is capped at 9.9% due to regulatory limits.

Future Outlook

The filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding PolyPid Ltd.'s future operations or financial performance.

Industry Context

This filing reflects a significant ownership position by a key investor group in PolyPid Ltd., a common occurrence in the biotechnology or pharmaceutical sector where strategic investors often take substantial stakes to support long-term development and commercialization efforts. Such large stakes can signal confidence in the company's pipeline or market potential, distinguishing it from companies with more fragmented ownership.

Related Party Transactions

• Morris Kahn is the ultimate sole beneficial shareholder of Aurum Ventures M.K.I. Ltd., and is deemed to share beneficial ownership of the shares held by Aurum.

Stakeholder Impact

• Shareholders: The presence of a large, committed shareholder group (Aurum Ventures and Morris Kahn) holding 28.1% of the company's shares may provide stability and confidence, potentially aligning with long-term value creation.
• Company Management: A significant shareholder with a long-term perspective can influence strategic decisions and corporate governance, potentially providing both support and oversight.

Key Dates

Recommendation

The filing primarily discloses a significant, stable ownership stake by Aurum Ventures and Morris Kahn, which is generally a positive signal of long-term commitment. However, it does not contain new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. The 'blocker' clause on warrant exercise introduces a nuance but doesn't fundamentally alter the existing ownership structure's implications. Therefore, a 'hold' recommendation is appropriate, advising investors to maintain their current position while awaiting further operational updates.

Keywords

PolyPid Ltd., Aurum Ventures, Morris Kahn, Schedule 13G, Beneficial Ownership, Ordinary Shares, Warrants, Shareholder Stake, SEC Filing, M8001Q118